Atypical trigeminal neuralgia is a form of facial nerve pain that produces a constant, background ache in addition to (or instead of) the brief electric shock-like jolts associated with the more common “typical” form. Where typical trigeminal neuralgia causes sudden, intense bursts of pain lasting seconds to two minutes, the atypical variant adds a persistent burning, aching, or throbbing component that can last hours or even be present all the time. This constant pain element makes it harder to diagnose and often harder to treat.
How It Differs From Typical Trigeminal Neuralgia
Typical trigeminal neuralgia, sometimes called Type 1 or TN1, is predominantly episodic. You feel sharp, stabbing jolts of pain triggered by everyday actions like chewing, brushing your teeth, or a breeze hitting your face. Between attacks, your face feels normal. About 74% of people with this form report attacks lasting under two minutes, though a significant minority experience episodes stretching to ten minutes.
Atypical trigeminal neuralgia, sometimes called Type 2 or TN2, is predominantly constant. The background pain is often described as a dull ache, burning sensation, or throbbing pressure. Many people with atypical TN still get the sharp, shock-like jolts layered on top of that constant pain, which is why some clinicians refer to this as “trigeminal neuralgia with concomitant continuous pain.” The International Classification of Headache Disorders recognizes this as a distinct subtype under both classical and idiopathic categories.
The distinction matters because treatment response differs between the two. Constant pain is generally more resistant to the standard medications that work well for the purely episodic form.
What Causes the Nerve Damage
The underlying mechanism is the same in both forms: damage to the protective insulation (myelin) surrounding the trigeminal nerve, the large nerve responsible for sensation across your forehead, cheek, and jaw. When that insulation breaks down, electrical signals can jump between neighboring nerve fibers in a process called ephaptic transmission. Pain signals fire in response to light touch or even spontaneously, without any trigger at all.
In 80% to 90% of cases, this damage comes from a blood vessel pressing against the trigeminal nerve root near the brainstem. The superior cerebellar artery is the culprit in roughly 75% to 80% of those cases, though veins and other arteries can also be responsible. The sustained compression gradually strips the nerve’s insulation, and over time, the pain pattern can shift from purely episodic to include a constant component. Multiple sclerosis accounts for about 2% to 4% of cases, because the disease itself attacks myelin throughout the nervous system, including around the trigeminal nerve.
Getting a Diagnosis
Diagnosing atypical trigeminal neuralgia can be frustrating because the constant aching pain overlaps with other conditions like temporomandibular joint disorder, dental problems, migraines, and other types of facial nerve pain. There is no single blood test or scan that confirms it. Diagnosis relies primarily on a detailed description of your pain: its location, quality, timing, and what triggers it.
MRI plays a key role in identifying whether a blood vessel is compressing the nerve. High-resolution 3D sequences performed on a 3.0 Tesla MRI scanner are significantly better than standard-strength scanners at detecting small vessels responsible for compression. These specialized sequences can visualize the exact point where a blood vessel contacts or distorts the nerve root. Newer imaging techniques can also detect subtle structural changes within the nerve itself, which helps confirm that damage has occurred even when compression is not obvious.
Medications for Pain Control
First-line treatment uses anticonvulsant medications, the same drugs prescribed for typical trigeminal neuralgia. Carbamazepine and oxcarbazepine are the standard starting points. These drugs work by calming the abnormal electrical firing in the damaged nerve. They tend to be more effective for the sharp, shock-like component of the pain than for the constant background ache, which is one reason atypical TN is considered more difficult to manage.
When first-line medications fall short, several second-line options exist. Lamotrigine, gabapentin, pregabalin, and baclofen are among the most commonly tried. Your doctor may combine two medications to address both the episodic and continuous pain components separately. The process of finding the right drug or combination often involves gradual dose increases over weeks, and side effects like drowsiness, dizziness, and cognitive fog are common at higher doses.
Botulinum toxin injections have shown promising results as an add-on treatment. In one study, about two-thirds of patients reported improvement after their first injection, with pain scores dropping significantly. Patients who received multiple rounds of injections, spaced at least three months apart, had better and more sustained results than those who received a single treatment. Pain relief from a single session lasted a median of about seven months in the best responders.
Surgical Options
When medications stop working or cause intolerable side effects, surgery becomes an option. Microvascular decompression (MVD) is the most definitive procedure. A surgeon opens a small window in the skull behind the ear, locates the blood vessel compressing the trigeminal nerve, and places a small cushion between them. For typical trigeminal neuralgia, this procedure has a cure rate of 80% to 98%.
Results for the atypical form are less predictable but still meaningful. One large study of 672 patients with atypical TN found that 47% experienced complete pain relief immediately after MVD, compared to 80% of those with the typical form. However, when partial relief was included, 87% of atypical TN patients saw significant improvement. Other studies have reported similar ranges: 79% to 92% of atypical TN patients experiencing at least partial pain relief after surgery. The recurrence rate across all types of trigeminal neuralgia following MVD is 10% to 30% over the long term.
The gap between complete and partial relief is important to understand. Many people with atypical TN find that surgery eliminates the sharp, jolting pain entirely but leaves some degree of the background ache. For some, this residual pain is mild enough to manage with low-dose medication. For others, it remains a significant problem.
Living With Atypical TN
The constant nature of atypical trigeminal neuralgia takes a toll that goes beyond the pain itself. Because the ache is always present, sleep disruption, difficulty concentrating, and emotional exhaustion are common. The condition tends to be chronic, and treatment is usually about management rather than cure. Most people cycle through periods of better and worse pain, and medication adjustments are a normal, ongoing part of life with this condition.
Finding effective treatment often takes time and persistence. The combination of a constant pain component that responds poorly to standard drugs, a surgical success rate that is lower than for typical TN, and the challenge of getting an accurate diagnosis in the first place means many people see multiple specialists before landing on a plan that works. Pain management clinics, neurologists with specific expertise in facial pain, and neurosurgeons experienced in MVD are the providers most likely to offer a comprehensive approach.